IDH2 and ductal breast carcinoma in situ: Survival analysis in DCIS revealed that higher IDH2 expression was correlated with shorter LRFI for all recurrences (HR = 2.4, 95% CI 1.3–4.5, p = 0.005, Fig. 3a) and a trend for association with shorter LRFI for invasive recurrences (HR = 1.9, 95% CI 0.9–4.4, p = 0.07 Fig. 3b) in patients treated solely with BCS without adjuvant radiotherapy.